These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 17678426)

  • 1. A role for B lymphocytes in anti-infective prion therapies?
    Tayebi M; Bate C; Hawke S; Williams A
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):631-8. PubMed ID: 17678426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated neuronal apoptosis: therapeutic implications for prion diseases.
    Tayebi M; Hawke S
    Immunol Lett; 2006 Jun; 105(2):123-6. PubMed ID: 16621033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in prion immunotherapy.
    Heppner FL; Aguzzi A
    Curr Opin Immunol; 2004 Oct; 16(5):594-8. PubMed ID: 15342005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiprion immunotherapy: to suppress or to stimulate?
    Aguzzi A; Sigurdson CJ
    Nat Rev Immunol; 2004 Sep; 4(9):725-36. PubMed ID: 15343371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies.
    Alexandrenne C; Hanoux V; Dkhissi F; Boquet D; Couraud JY; Wijkhuisen A
    J Neuroimmunol; 2009 Apr; 209(1-2):50-6. PubMed ID: 19232746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies.
    Dumoulin M; Dobson CM
    Biochimie; 2004; 86(9-10):589-600. PubMed ID: 15556268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B lymphocytes in prion neuroinvasion: central or peripheral players?
    Collinge J; Hawke S
    Nat Med; 1998 Dec; 4(12):1369-70. PubMed ID: 9846572
    [No Abstract]   [Full Text] [Related]  

  • 8. Intrabody applications in neurological disorders: progress and future prospects.
    Miller TW; Messer A
    Mol Ther; 2005 Sep; 12(3):394-401. PubMed ID: 15964243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prions: protein aggregation and infectious diseases.
    Aguzzi A; Calella AM
    Physiol Rev; 2009 Oct; 89(4):1105-52. PubMed ID: 19789378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generating antibodies against the native form of the human prion protein (hPrP) in wild-type animals: a comparison between DNA and protein immunizations.
    Alexandrenne C; Wijkhuisen A; Dkhissi F; Hanoux V; Créminon C; Boquet D; Couraud JY
    J Immunol Methods; 2009 Feb; 341(1-2):41-9. PubMed ID: 19027745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies.
    Bade S; Frey A
    Expert Rev Vaccines; 2007 Apr; 6(2):153-68. PubMed ID: 17408366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cells and prions: a license to replicate.
    Nuvolone M; Aguzzi A; Heikenwalder M
    FEBS Lett; 2009 Aug; 583(16):2674-84. PubMed ID: 19527722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More tools for prion research.
    Bradbury J
    Drug Discov Today; 2004 Oct; 9(19):821-2. PubMed ID: 15381128
    [No Abstract]   [Full Text] [Related]  

  • 14. Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity.
    Horiuchi M; Karino A; Furuoka H; Ishiguro N; Kimura K; Shinagawa M
    Virology; 2009 Nov; 394(2):200-7. PubMed ID: 19766283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overactivation of calcineurin induced by amyloid-beta and prion proteins.
    Agostinho P; Lopes JP; Velez Z; Oliveira CR
    Neurochem Int; 2008 May; 52(6):1226-33. PubMed ID: 18295934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity.
    Müller-Schiffmann A; Petsch B; Leliveld SR; Muyrers J; Salwierz A; Mangels C; Schwarzinger S; Riesner D; Stitz L; Korth C
    Mol Immunol; 2009 Feb; 46(4):532-40. PubMed ID: 18973947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases.
    Sakaguchi S; Ishibashi D; Matsuda H
    Expert Opin Ther Pat; 2009 Jul; 19(7):907-17. PubMed ID: 19514955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion proteins: physiological functions and role in neurological disorders.
    Hu W; Kieseier B; Frohman E; Eagar TN; Rosenberg RN; Hartung HP; Stüve O
    J Neurol Sci; 2008 Jan; 264(1-2):1-8. PubMed ID: 17707411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin.
    Haviv Y; Avrahami D; Ovadia H; Ben-Hur T; Gabizon R; Sharon R
    Arch Neurol; 2008 Jun; 65(6):762-75. PubMed ID: 18541796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
    Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
    J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.